aspirin has been researched along with Cardiac Output, Low in 8 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Cardiac Output, Low: A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with Dilated Cardiomyopathy (DCM) were randomised to receive either warfarin or placebo." | 2.72 | Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. ( Cokkinos, DV; Haralabopoulos, GC; Kostis, JB; Toutouzas, PK, 2006) |
| "Aspirin has been associated with adverse heart failure outcomes, probably because of a blunting interaction with angiotensin-converting enzyme (ACE) inhibitors." | 2.72 | Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure. ( Jug, B; Keber, I; Sabovic, M; Sebestjen, M, 2006) |
| " Daily dosage of ACE inhibitors and particularly of beta-blockers was on average below the recommended target dose." | 1.32 | The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. ( Aguilar, JC; Cleland, J; Cohen-Solal, A; Dietz, R; Eastaugh, J; Follath, F; Freemantle, N; Gavazzi, A; Hobbs, R; Komajda, M; Korewicki, J; Madeira, HC; Mason, J; Moiseyev, VS; Preda, I; Swedberg, K; Van Gilst, WH; Widimsky, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Komajda, M | 1 |
| Follath, F | 1 |
| Swedberg, K | 1 |
| Cleland, J | 1 |
| Aguilar, JC | 1 |
| Cohen-Solal, A | 1 |
| Dietz, R | 1 |
| Gavazzi, A | 1 |
| Van Gilst, WH | 1 |
| Hobbs, R | 1 |
| Korewicki, J | 1 |
| Madeira, HC | 1 |
| Moiseyev, VS | 1 |
| Preda, I | 1 |
| Widimsky, J | 1 |
| Freemantle, N | 1 |
| Eastaugh, J | 1 |
| Mason, J | 1 |
| Pullicino, P | 1 |
| Thompson, JL | 1 |
| Barton, B | 1 |
| Levin, B | 1 |
| Graham, S | 1 |
| Freudenberger, RS | 1 |
| Cokkinos, DV | 1 |
| Haralabopoulos, GC | 1 |
| Kostis, JB | 1 |
| Toutouzas, PK | 1 |
| Jug, B | 1 |
| Sebestjen, M | 1 |
| Sabovic, M | 1 |
| Keber, I | 1 |
| Matsukawa, M | 1 |
| Kaikita, K | 1 |
| Soejima, K | 1 |
| Fuchigami, S | 1 |
| Nakamura, Y | 1 |
| Honda, T | 1 |
| Tsujita, K | 1 |
| Nagayoshi, Y | 1 |
| Kojima, S | 1 |
| Shimomura, H | 1 |
| Sugiyama, S | 1 |
| Fujimoto, K | 1 |
| Yoshimura, M | 1 |
| Nakagaki, T | 1 |
| Ogawa, H | 1 |
| Cleland, JG | 1 |
| Pfeffer, MA | 1 |
| Braunvald, Iu | 1 |
| Moĭe, LA | 1 |
| Basta, L | 1 |
| Kaddi, TE | 1 |
| Dévis, BR | 1 |
| Geltman, EM | 1 |
| Goldman, S | 1 |
| Fleĭker, GS | 1 |
| Barron, HV | 1 |
| Michaels, AD | 1 |
| Maynard, C | 1 |
| Every, NR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)[NCT05204238] | 998 participants (Actual) | Observational | 2020-09-01 | Active, not recruiting | |||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for aspirin and Cardiac Output, Low
| Article | Year |
|---|---|
ACE inhibitors for the prevention and treatment of heart failure: why are they 'under-used'?
Topics: Aging; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiac Output, Low; Clinical Trials as To | 1995 |
4 trials available for aspirin and Cardiac Output, Low
| Article | Year |
|---|---|
Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design.
Topics: Anticoagulants; Aspirin; Cardiac Output, Low; Double-Blind Method; Female; Goals; Humans; Platelet A | 2006 |
Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Cardiac Output, Low; Cardiomyopathy, Dilated; Double-B | 2006 |
Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Output, Low; Clopidogrel; Cross-Over Studies; Disease Prog | 2006 |
[Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Captopril; Cardiac Output, Low | 1993 |
3 other studies available for aspirin and Cardiac Output, Low
| Article | Year |
|---|---|
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; C | 2003 |
Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; A | 2007 |
Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary | 1998 |